Potential absence of prognostic implications of severe preoperative hypercalcitoninemia in medullary thyroid carcinoma

Endocrine Practice

Volumn 9, Issue 4, 2003, Pages 284-289

  Zangeneh, Farhad ^a   Gharib, Hossein ^a   Goellner, John R ^a   Kao, Pai Chih ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; PENTAGASTRIN;

ADULT; AGED; ARTICLE; BLOOD; CASE REPORT; FEMALE; HUMAN; MALE; MEDULLARY CARCINOMA; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RADIOIMMUNOASSAY; RECURRENT DISEASE; STIMULATION; THYROID TUMOR; THYROIDECTOMY;

ADULT; AGED; BIOLOGICAL MARKERS; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; FEMALE; HUMANS; MALE; MIDDLE AGED; PENTAGASTRIN; PROGNOSIS; RADIOIMMUNOASSAY; RECURRENCE; STIMULATION, CHEMICAL; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 2142805215     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.9.4.284     Document Type: Article

References (32)

1. Pommier RF, Brennan MF. Medullary thyroid carcinoma. Endocrinologist. 1992;2:393-405.
2. Gharib H, McConahey WM, Tiegs RD, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc. 1992;67:934-940.
3. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: recent advances and management update. Thyroid. 1995;5:407-424.
4. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83:2638-2648.
5. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 1994;6:70-74.
6. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367:375-376.
7. Heshmati HM, Gharib H, Khosla S, Abu-Lebdeh HS, Lindor NM, Thibodeau SN. Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. Mayo Clin Proc. 1997;72:430-436.
8. Tsai MS, Ledger GA, Khosla S, Gharib H, Thibodeau SN. Identification of multiple endocrine neoplasia, type 2 gene carriers using linkage analysis and analysis of the RET proto-oncogene. J Clin Endocrinol Metab. 1994;78:1261-1264.
9. Lips CJ, Landsvater RM, Hoppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 1994;331:828-835.
10. Wells SA Jr. New approaches to the patient with medullary carcinoma of the thyroid gland. Thyroid Today. 1994;17:1-9.
11. Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med. 1997;103:60-69.
12. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab. 1997;82:1589-1593.
13. Niccoli P, Wion-Barbot N, Caron P, et al (The French Medullary Study Group). Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. J Clin Endocrinol Metab. 1997;82:338-341.
14. Thyroid Carcinoma Task Force. American Association of Clinical Endocrinologists/American College of Endocrinology medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract. 2001;7:202-220.
15. Giuffrida D, Gharib H. Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol. 1998;9:695-701.
16. Tisell LE, Dilley WG, Wells SA Jr. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery. 1996;119:34-39.
17. Ball DW, Baylin SB, Bustros AC. Medullary thyroid carcinoma. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 930-943.
18. Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg. 1998;22:562-567.
19. Girelli ME, Nacamulli D, Pelizzo MR, et al. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986. Thyroid. 1998;8:517-523.
20. Modigliani E, Franc B, Niccoli-Sire P. Diagnosis and treatment of medullary thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:631-649.
21. Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid. 2000;10:919-922.
22. Wells SA Jr, Baylin SB, Leight GS, Dale JK, Dilley WG, Farndon JR. The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Ann Surg. 1982;195:595-599.
23. Cohen R, Campos JM, Salaun C, et al (Groupe d'Etudes des Tumeurs a Calcitonine [GETC]). Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab. 2000;85:919-922.
24. Gharib H, Kao PC, Heath H III. Determination of silica-purified plasma calcitonin for the detection and management of medullary thyroid carcinoma: comparison of two provocative tests. Mayo Clin Proc. 1987;62:373-378.
25. Kao PC, Gharib H. Clinical performance of an extraction calcitonin radioimmunoassay. Mayo Clin Proc. 1993;68:1165-1170.
26. Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U, Dralle H. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer. 2000;88:1909-1915.
27. Saad MF, Ordonez NG, Guido JJ, Samaan NA. The prognostic value of calcitonin immunostaining in medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1984;59:850-856.
28. Pyke CM, Hay ID, Goellner JR, Bergstralh EJ, van Heerden JA, Grant CS. Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma [with discussion]. Surgery. 1991;110:964-971.
29. Hyer SL, Vini L, A'Hern R, Harmer C. Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol. 2000;26:686-690.
30. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-1148.
31. O'Riordain DS, O'Brien T, Weaver AL, et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery. 1994;116:1017-1023.
32. Modigliani E, Cohen R, Campos JM, et al (The GETC Study Group. Groupe d'Etudes des Tumeurs a Calcitonine). Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf). 1998;48:265-273.